Volume : 13, Issue : 01, January – 2026

Title:

NEUROPROTECTIVE EFECT OF POLYGALA MYRTIFOLIA ON PARKINSONS DISEASE IN MALE SPRAGUE DAWLEY RATS

Authors :

Thatikonda Sathwika, Dr. I Veena Rani*

Abstract :

Chlorpromazine (CPZ), a widely used antipsychotic, is associated with neurotoxicity characterized by oxidative stress, mitochondrial dysfunction, and dopaminergic depletion, leading to motor deficits and neurochemical imbalances. This study evaluated the neuroprotective effects of Polygala extract against CPZ-induced toxicity in rats. Four groups were treated: vehicle control, CPZ alone, and CPZ combined with Polygala extract at 100 mg/kg and 200 mg/kg doses for 21 days.
Results demonstrated that CPZ significantly increased lipid peroxidation, midbrain calcium levels, and dopamine metabolites while decreasing antioxidant enzyme activities (catalase, SOD, glutathione reductase), mitochondrial Complex I activity, and dopamine levels. Co-treatment with Polygala extract dose-dependently reversed these changes, restoring antioxidant defenses, mitochondrial function, calcium homeostasis, and dopaminergic balance. Behavioral assessments, including rotarod and catalepsy tests, showed improved motor coordination and reduced neurotoxicity with Polygala treatment.
The findings suggest that Polygala extract exerts potent neuroprotective effects by mitigating oxidative stress, preserving mitochondrial integrity, and supporting dopaminergic neurotransmission. These results highlight its potential as a natural adjunct therapy to prevent or reduce antipsychotic-induced neurotoxicity.
Keywords: Polygala extract, Chlorpromazine, lipid peroxidation, midbrain calcium levels

Cite This Article:

Please cite this article in press I veena Rani et al., Neuroprotective Efect Of Polygala Myrtifolia On Parkinsons Disease In Male Sprague Dawley Rats, Indo Am. J. P. Sci, 2026; 13(01).

REFERENCES:

1. Schober A. Classic toxin-induced animal models of Parkinson’s disease: 6-OHDA and MPTP. Cell Tissue Res. 2004;318:215-24.
2. Alexi T, Borlongan CV, Faull LM, Williams CE et al. NAAEURoprotective strategies for basal ganglia degeneration: Parkinson’s and Huntington’s diseases. Prog NAAEURobiol. 2000;60:409-70.
3. Bartels AL, Leenders KL. Parkinson’s disease: The syndrome, the pathogenesis and pathophysiology. Cortex. 2009;1-7.
4. Parkinson J. An essay on the shaking palsy 1817. J NAAEURopsychiatry Clin NAAEURosci. 2002;14:223-36.
5. Langston JW, Ballard JW, Tetrud JW, Irwin I et al. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 1983;219:979-80.
6. Lonneke ML, Monique MB. Epidemiology of Parkinson’s disease. NAAEURology. 2006; 51(5):521-29.
7. Floyed E. NAAEURotransmission and the central nervous system. In Goodman and Gillman’s, editor. The pharmacological basis of therapeutics. 11th ed. New York: McGraw hill publication; 2007.p.527.
8. William D. Serge Przedborski Parkinson’s Disease: Mechanisms and Models. NAAEURon. 2003;39:889-09.
9. Fearnley JM, Lees AJ. Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain res. 1991;114:2283-301.
10. Vingerhoets FJ, Snow BJ, Tetrud JW, Langston JW et al. Positron emission tomographic evidence for progression of human MPTP-induced dopaminergic lesions. Ann NAAEURol.1994;36:765-70.
11. Jenner P. Mitochondria, monoamine oxidase B and Parkinson’s disease. Basal Ganglia. 2012;2:S3-S7.
12. Foley P, Gerlach M, Youdim MBH, Riederer P. MAO-B inhibitors: multiple roles in the therapy of nAAEURodegenerative disorders? Parkinsonism Relat D. 2000;6:25-47.
13. Bhattacharya SK, Satya KS, Ghosal S. Anitioxidant activity of glycowithanolides from Withania somnifera. Indian J Exp Biol. 1997;35:236-39.
14. RajaSankara S, Manivasagamb T, Sankard V. Withania somnifera root extract improves catecholamines and physiological abnormalities seen in a Parkinson’s disease model mouse. J of Ethnopharmacol. 2009;125(3):369-73.
15. Rawala A, Muddeshwarb M, Biswas S. Effect of Rubia cordifolia, Fagonia cretica linn, and Tinospora cordifolia on free radical generation and lipid peroxidation during oxygen-glucose deprivation in rat hippocampal slices. Biochem Bioph Res Co. 2004;324(2):588-96.
16. Antony SA, Bebroy P, Vadivelan R. Amelioration of CNS Toxicities of L-Dopa in Experimental Models of Parkinson’s disease by Concurrent Treatment with Tinospora cordifolia. Hygeia. 2010;2(1):28-37.
17. Kim MS, Lee JI, Lee WY, Kim SE et al. NAAEURoprotective effect of Ginkgo biloba L. extract in a rat model of Parkinson’s disease. Phytother Res. 2004;18(8):663-66.
18. Ilhan A, Gurel A, Armutcu F. Ginkgo biloba prevents mobile phone-induced oxidative stress in rat brain. Clinica Chimica Acta. 2004;340(1-2)153-62.
19. Kong LD, Cheng CHK, Tan RX. Monoamine oxidase inhibitors from rhizoma of Coptis chinensis. Planta Med. 2001; 67:74-76.
20. Al-Baghdadi OB, Prater NI, Schyf CJ, Geldenhuys WJ. Inhibition of monoamine oxidase by derivatives of piperine, an alkaloid from the pepper plant Piper nigrum, for possible use in Parkinson’s disease. Bioorg Med Chem Lett. 2012;22:7183-88.
21. Han YN, Noh DB, Han DS. Studies on the monoamine oxidase inhibitors of medicinal plants I. Isolation of MAO-B inhibitors from Chrysanthemum indicum. Arch Pharm Res. 1987;10:142-47.
22. Bar O, Amit T, Kupershmidt L, Aluf Y. NAAEURoprotective and nAAEURorestorative activities of a novel iron chelator-brain selective monoamine oxidase-A/monoamine oxidase-B inhibitor in animal models of Parkinson’s disease and aging. NAAEURobiol Aging. 2015; 36:1529-42.